Reckitt Benckiser Group PLC
Reckitt Benckiser Group PLC agreed to pay $50 million to settle FTC antitrust charges that it engaged in a deceptive 'product hopping' scheme to block generic competition to its branded opioid-dependence drug Suboxone. The company allegedly misrepresented that the film version of Suboxone was safer than tablets — specifically that children were less likely to be accidentally exposed — in order to shift prescriptions to a patent-protected formulation before generics entered the market. Its former subsidiary Indivior agreed to pay an additional $10 million. Nearly $60 million in total payments were distributed to affected consumers.
Flagged claims (1)
the film version of Suboxone was safer than Suboxone tablets because children are less likely to be accidentally exposed to the film product
Required actions (3)
Reckitt Benckiser Group plc has agreed to pay $50 million to settle Federal Trade Commission charges that it violated the antitrust laws through a deceptive scheme to thwart lower-priced generic competition to its branded drug Suboxone.
Indivior has agreed to pay an additional $10 million to settle FTC charges.
On May 10, 2021, the FTC announced that it sent nearly $60 million in payments to consumers who were victims of the scheme.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most pharmacy / compounding sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker